These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 19349140)
1. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer]. Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140 [No Abstract] [Full Text] [Related]
2. [Nasal septum perforation and bevacizumab]. Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582 [TBL] [Abstract][Full Text] [Related]
3. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Traina TA; Norton L; Drucker K; Singh B Oncologist; 2006; 11(10):1070-1. PubMed ID: 17110625 [No Abstract] [Full Text] [Related]
4. [A complete response following treatment with Paclitaxel and bevacizumab for metastatic breast cancer]. Tsubota Y; Sueoka N; Yamamoto D Gan To Kagaku Ryoho; 2014 Nov; 41(12):1954-6. PubMed ID: 25731387 [TBL] [Abstract][Full Text] [Related]
5. Herceptin-taxol related hand and foot syndrome. Merimsky O; Inbar MJ Isr Med Assoc J; 2000 Oct; 2(10):786. PubMed ID: 11344738 [No Abstract] [Full Text] [Related]
6. Managing adverse events in the use of bevacizumab and chemotherapy. Blowers E; Hall K Br J Nurs; 2009 Mar 26-Apr 8; 18(6):351-6, 358. PubMed ID: 19329899 [TBL] [Abstract][Full Text] [Related]
7. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer. Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature. Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Lecarpentier E; Ouaffi L; Mir O; Berveiller P; Maurel M; Pujade-Lauraine E; Bouillot JL; Veyrie N Invest New Drugs; 2011 Dec; 29(6):1500-3. PubMed ID: 20676743 [TBL] [Abstract][Full Text] [Related]
10. Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report. Yanagihara K; Takei H; Iida S; Yamashita K; Kurita T; Iwamoto M; Saegusa H; Uchida E J Nippon Med Sch; 2014; 81(5):333-6. PubMed ID: 25391703 [TBL] [Abstract][Full Text] [Related]
11. Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Coltelli L; Allegrini G; Orlandi P; Giuntini N; Alì G; Fioravanti A; Bona E; Barletta MT; Fontanini G; Del Tacca M; Danesi R; Falcone A; Bocci G Pharmacogenomics; 2009 Aug; 10(8):1225-9. PubMed ID: 19663667 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab combined with two-weekly paclitaxel as first-line therapy for metastatic breast cancer. Kountourakis P; Doufexis D; Maliou S; Karagiannis A; Kardara E; Margari C; Sykoutri D; Tzovaras A; Ardavanis A Anticancer Res; 2010 Jul; 30(7):2969-71. PubMed ID: 20683040 [TBL] [Abstract][Full Text] [Related]
13. Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel. Philippin-Lauridant G; Thureau S; Ouvrier MJ; Blot E Ann Oncol; 2008 Nov; 19(11):1977-8. PubMed ID: 18801882 [No Abstract] [Full Text] [Related]
14. Modified resistance to chemotherapy and trastuzumab by bevacizumab in locally recurrent breast cancer. Farhat MH; El-Saghir NS; Shamseddine AI Breast; 2009 Feb; 18(1):66-8. PubMed ID: 19013064 [TBL] [Abstract][Full Text] [Related]
15. Adverse events in bevacizumab and chemotherapy: patient management. Blowers E; Hall K Br J Nurs; 2009 Apr 9-22; 18(7):424-8. PubMed ID: 19373187 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Labidi SI; Bachelot T; Ray-Coquard I; Mosbah K; Treilleux I; Fayette J; Favier B; Galy G; Blay JY; Guastalla JP Clin Breast Cancer; 2009 May; 9(2):118-21. PubMed ID: 19433393 [TBL] [Abstract][Full Text] [Related]
17. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab. Lazzati V; Zygoń J; Lohsiriwat V; Veronesi P; Petit JY Aesthetic Plast Surg; 2010 Dec; 34(6):796-7. PubMed ID: 20567970 [No Abstract] [Full Text] [Related]
18. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309 [TBL] [Abstract][Full Text] [Related]
19. Safety of bevacizumab in patients with metastatic breast cancer. Hamilton EP; Blackwell KL Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772 [TBL] [Abstract][Full Text] [Related]
20. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]